Your shopping cart is currently empty

WLBU2 is an engineered cationic antimicrobial peptide (eCAP) designed to overcome the sensitivity issues of natural antimicrobial peptides (AMPs) in various environments. WLBU2 exhibits rapid bactericidal activity and has a minimum inhibitory concentration (MIC) value of ≤ 10 μM against numerous Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, and Escherichia coli. It effectively prevents biofilm formation by Pseudomonas aeruginosa and retains its activity in mucus-rich, low pH, and high salt conditions, without adverse effects on human respiratory epithelial cells. Additionally, WLBU2 is applicable for studying cystic fibrosis (CF) and Pseudomonas aeruginosa infections.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | WLBU2 is an engineered cationic antimicrobial peptide (eCAP) designed to overcome the sensitivity issues of natural antimicrobial peptides (AMPs) in various environments. WLBU2 exhibits rapid bactericidal activity and has a minimum inhibitory concentration (MIC) value of ≤ 10 μM against numerous Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, and Escherichia coli. It effectively prevents biofilm formation by Pseudomonas aeruginosa and retains its activity in mucus-rich, low pH, and high salt conditions, without adverse effects on human respiratory epithelial cells. Additionally, WLBU2 is applicable for studying cystic fibrosis (CF) and Pseudomonas aeruginosa infections. |
| In vitro | WLBU2 inhibits biofilm formation of Pseudomonas aeruginosa on non-biological surfaces and human cystic fibrosis airway epithelial cells (CFAECs) at concentrations of 5-90 μM for 24 hours on abiotic surfaces and 10-100 μM for 5 hours on CFAECs. At a concentration of 50 μM for 5 hours, it retains biofilm prevention efficacy in environments with high salt (100 mM NaCl) and low pH (6.5-7.0). When used at 20 μM for 5 hours in CFAECs, WLBU2 shows a synergistic effect with Tobramycin, Ciprofloxacin, Ceftazidime, and Meropenem, but not with Colistin. The MIC of WLBU2 for Klebsiella pneumoniae is 7.943 μM, and for clinical isolates of Acinetobacter baumannii, it is 7.484 μM. Additionally, the MBC values for bacterial isolates are the same as their MIC values, suggesting its bactericidal properties. |
| Molecular Weight | 3400.11 |
| Formula | C151H260N66O25 |
| Cas No. | 847061-43-2 |
| Smiles | C([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC=1C=2C(NC1)=CC=CC2)NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCCNC(=N)N)=O)=O)C(C)C)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)[C@@H](C)C)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=3C=4C(NC3)=CC=CC4)C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)CCCNC(=N)N)=O)C(C)C)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)C(C)C)=O)[C@H](C)C)=O)CCCNC(=N)N)=O)[C@@H](C)C)=O)C(C)C)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)[C@H](C)C)=O)C=5C=6C(NC5)=CC=CC6 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.